Unknown PHASE1/PHASE2 INTERVENTIONAL NCT00188383

Effects of N-Methyl-D-Aspartate (NMDA)-Receptor Antagonism on Hyperalgesia, Opioid Use, and Pain After Radical Prostatectomy

Effects of NMDA-Receptor Antagonism on Hyperalgesia, Opioid Use, and Pain After Radical Prostatectomy in Young and Elderly Patients

Sponsor: Canadian Institutes of Health Research (CIHR)

Conditions Hyperalgesia Pain Prostate Cancer

Interventions Amantadine

Updated 5 times since 2017 Last updated: Mar 13, 2006 Started: Jan 31, 2004 Completion: Dec 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Hyperalgesia and Pain, this trial is ongoing. The trial is conducted by Canadian Institutes of Health Research (CIHR) and has accumulated 5 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE1_PHASE2

First recorded

Jan 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Canadian Institutes of Health Research (CIHR)
University Health Network, Toronto

Data source: University Health Network, Toronto

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada